Intellectual Property Rights: Provisions on intellectual property (IP) rights should ensure governments may enact robust limitations and exceptions to rights, and limitations on remedies. IP enforcement should be proportionate and respect the right to a judicial remedy. In some areas,…
Notes from EP Industry Committee debate on clinical trials
Industry Committee debates medical research transparency and European Commission claims reporting requirements hurt small non-commercial researchers Today the Industry, Research and Energy Committee debated their opinion of the Clinical Trial Regulation. The rapporteur of the Opinion is French Green Michelle…
EP´s Industry committee debates clinical trial transparency; Commission defends “small guys”
Industry Committee debates medical research transparency and European Commission claims reporting requirements hurt small non-commercial researchers Today the Industry, Research and Energy Committee debated their opinion of the Clinical Trial Regulation. The rapporteur of the Opinion is French…
Tough fight for medical clinical trial transparency in European Parliament
Debate in European Parliament Environment and Health Committee on Clinical Trial Regulation 19-2-2013 Today the first major discussion on the future of clinical trials in the EU took place in the lead committee on this legislative report. Rapporteur Glenis…
Transparency, ethics and defence of public health
Questions and answers on the Clinical Trial Regulation and transparency. Why transparency? Clinical research is enormously complex and today most doctors and patients do not receive enough information to know the real effect of the medicines they are prescribing and…
Sample letter to members of EU Council in favour of Open Access in H2020
Dear We are writing you to express our agreement with the mandatory open access policy in the Rules of Participation for Horizon 2020 that is now being negotiated in by the Council, the Commission and the European Parliament. We…